Borean Pharma granted US patent
Borean Pharma, a biopharmaceutical and protein engineering company, has been granted a US patent for its atherosclerosis drug candidate, Trimeric Apolipoprotein A-I, which is currently in preclinical development.
Borean Pharma, a biopharmaceutical and protein engineering company, has been granted a US patent for its atherosclerosis drug candidate, Trimeric Apolipoprotein A-I, which is currently in preclinical development.
Atherosclerosis is a trimerised version of the naturally occurring protein, Apolipoprotein A-I (ApoA-I) - the major protein component of high-density lipoprotein (HDL), also known as 'good cholesterol'. Plasma levels of HDL and ApoA-I have been found to be inversely correlated with the incidence of atherosclerosis, and trimeric Apo A-I has been shown to stabilise and inhibit plaque formation in mice arteries more effectively than the naturally occurring monomeric form.
Borean initially developed the trimeric ApoA-I protein in collaboration with Proteopharma, before taking it over in February 2004.
Recently, a Phase II clinical trial demonstrated that a dimeric variant of Apolipoprotein A-I, ApoA-I Milano, reduced the fatty arterial plaque that triggers most heart attacks by an average of 4.2%.